Latest Personalis News & Updates

See the latest news and media coverage for Personalis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Personalis

Cancer genomics and diagnostics company

personalis.com

Headquarters: Fremont, United States
Founded year: 2011
Company type: Public company
Number of employees: 400–500
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Personalis

In short: Personalis agreed to be acquired by Tempus AI in a ~$1.5B all-stock deal and posted strong Q2 growth with expanded Medicare coverage.

Company announcements

September 18 Personalis

Richard Chen files form 4 for Personalis

The statement reports changes in beneficial ownership of securities filed on September 22, 2026, referencing a document date of September 18, 2026.

August 4 Personalis

Personalis reports second quarter 2026 financial results

Q2 revenue grew 30% to $22.4 million, with clinical revenue surging 442%. The company secured Medicare coverage and announced a merger with Tempus AI.

July 20 Personalis

Personalis announces its acquisition by Tempus for $1.5 billion

The all-stock deal integrates Personalis MRD technology into Tempus AI platform. Closing is expected in late 2026 or early 2027.

July 14 Personalis

Personalis obtains UKCA marking for British MRD diagnostics

This approval enables clinical deployment across England, Wales, and Scotland while bolstering multinational oncology trials through a commercial partnership with Link Medical Solutions Ltd.

Media coverage

September 29 Stock Titan

Stock is the default in Tempus AI (TEM)'s proposed Personalis merger, but cash is an option.

Cash may cover up to 50% of Personalis shares, applied equally across holders and subject to tax-related reduction. Closing needs shareholder approval.

September 17 Timothy Sykes

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

The planned ~$1.5B Personalis acquisition raises the stakes. At $16.25 per share, Tempus AI is making a big bet that integrating Personalis will deepen its...

September 17 Simply Wall St

Top 3 AI Healthcare Stocks To Watch In September 2026 - Simply Wall St News

"The biggest development is the $1.5 billion acquisition of Personalis, which strengthens Tempus’ position in molecular residual disease (MRD) testing.

August 31 MLex

Tempus AI pulling, refiling US antitrust paperwork for Personalis buyout

Health technology company Tempus AI withdrew the US federal premerger antitrust form for its proposed acquisition of cancer diagnostics firm Personalis on Aug. 31, and...

Never miss news about Personalis

Track Personalis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Personalis competitors & trending companies

Browse news for competitors to Personalis and other trending companies.